Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone732-524-0400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$81.58 billion
Profitability
Miscellaneous
Employees135,100
Next Earnings Date1/28/2020 (Estimated)
OptionableOptionable
Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Thursday, October 17th. Investors of record on Tuesday, November 26th will be paid a dividend of $0.95 per share on Tuesday, December 10th. This represents a $3.80 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date of this dividend is Monday, November 25th. View Johnson & Johnson's Dividend History.
How will Johnson & Johnson's stock buyback program work?
Johnson & Johnson announced that its Board of Directors has authorized a stock buyback program on Monday, December 17th 2018, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 1.5% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday, October, 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $2.00 by $0.12. The firm had revenue of $20.73 billion for the quarter, compared to analysts' expectations of $20.14 billion. Johnson & Johnson had a return on equity of 39.54% and a net margin of 21.09%. The business's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.05 earnings per share. View Johnson & Johnson's Earnings History.
When is Johnson & Johnson's next earnings date?
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson issued an update on its FY19 earnings guidance on Tuesday, October, 15th. The company provided earnings per share (EPS) guidance of $8.62-8.67 for the period, compared to the Thomson Reuters consensus estimate of $8.61. The company issued revenue guidance of $81.8-82.3 billion, compared to the consensus revenue estimate of $81.59 billion.
What price target have analysts set for JNJ?
12 analysts have issued twelve-month target prices for Johnson & Johnson's shares. Their forecasts range from $140.00 to $169.00. On average, they anticipate Johnson & Johnson's stock price to reach $152.10 in the next year. This suggests a possible upside of 19.1% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
What is the consensus analysts' recommendation for Johnson & Johnson?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Johnson & Johnson.
Has Johnson & Johnson been receiving favorable news coverage?
News coverage about JNJ stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Johnson & Johnson earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Johnson & Johnson.
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Johnson & Johnson own?
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Mr. Alex Gorsky, Chairman & CEO (Age 59)
- Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
- Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
- Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)
- Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)
Who are Johnson & Johnson's major shareholders?
Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional investors include CIBC Private Wealth Group LLC (0.09%), PGGM Investments (0.08%), Manning & Napier Group LLC (0.08%), DNB Asset Management AS (0.07%), Assenagon Asset Management S.A. (0.06%) and Robeco Institutional Asset Management B.V. (0.06%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Joaquin Duato, Marillyn A Hewson, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Which major investors are selling Johnson & Johnson stock?
JNJ stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Hexavest Inc., Gateway Investment Advisers LLC, Ellevest Inc., Robeco Institutional Asset Management B.V., Oakbrook Investments LLC, Accurate Investment Solutions Inc. and Northstar Investment Advisors LLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.
Which major investors are buying Johnson & Johnson stock?
JNJ stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, State of Alaska Department of Revenue, DNB Asset Management AS, Pwmco LLC, PGGM Investments, Beech Hill Advisors Inc. and Pacer Advisors Inc.. Company insiders that have bought Johnson & Johnson stock in the last two years include Charles Prince and Marillyn A Hewson. View Insider Buying and Selling for Johnson & Johnson.
How do I buy shares of Johnson & Johnson?
Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of JNJ stock can currently be purchased for approximately $127.70.
How big of a company is Johnson & Johnson?
Johnson & Johnson has a market capitalization of $337.02 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe.View Additional Information About Johnson & Johnson.
What is Johnson & Johnson's official website?
How can I contact Johnson & Johnson?
Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
